Literature DB >> 19728060

Phosphodiesterase 4B2 gene is an effector of Toll-like receptor signaling in astrocytes.

Elizabeth Borysiewicz1, Daniel Fil, Daniel Dlaboga, James M O'Donnell, Gregory W Konat.   

Abstract

Cyclic AMP is part of an endogenous mechanism that downregulates inflammatory response, and its intracellular concentration is regulated chiefly by cyclic nucleotide phosphodiesterases type 4. The goal of the present study was to determine whether phosphodiesterases 4 are involved in the inflammatory response of astrocytes mediated by Toll-like receptors. Astrocyte cultures established from newborn rat brain were challenged with lipoteichoic acid, a ligand of Toll-like receptor 2, polyinosinic-polycytidylic acid, a ligand of Toll-like receptor 3, or lipopolysaccharide, a ligand of Toll-like receptor 4. After 24 h the expression of genes encoding phosphodiesterase 4A, phosphodiesterase 4B and phosphodiesterase 4D was determined by real time reverse transcription polymerase chain reaction. The challenge of astrocytes with the ligands profoundly up-regulated expression of the phosphodiesterase 4B mRNA, while the phosphodiesterase 4A and 4D mRNA was either unaffected or downregulated. Moreover, Toll-like receptor ligation specifically up-regulated expression of the phosphodiesterase 4B2 transcriptional variant. Thus, polyinosinic-polycytidylic acid, lipopolysaccharide and lipoteichoic acid induced approximately 7-, 5- and 4-fold up-regulation of the message, respectively. Toll-like receptor ligation also led to an over 2-fold increase in the protein level of phosphodiesterase 4B2 as revealed by immunoblot analysis. The inactivation of Rho proteins by pretreatment with toxin B form C. difficile enhanced ligation-induced up-regulation of the phosphodiesterase 4B2 message by 4-9-fold. However, in spite of this increase in the message abundance, there was no increase in the protein level compared to cells challenged with the ligands alone. These results demonstrate that the phosphodiesterase 4B2 gene is an effector of Toll-like receptor signaling in astrocytes, and that its up-regulation at the protein level is controlled by complex mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728060     DOI: 10.1007/s11011-009-9150-9

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  34 in total

1.  mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module.

Authors:  K L Dodge; S Khouangsathiene; M S Kapiloff; R Mouton; E V Hill; M D Houslay; L K Langeberg; J D Scott
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

Review 2.  Immune function of astrocytes.

Authors:  Y Dong; E N Benveniste
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

Review 3.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

Authors:  T J Torphy
Journal:  Am J Respir Crit Care Med       Date:  1998-02       Impact factor: 21.405

Review 4.  New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.

Authors:  M S Barnette; D C Underwood
Journal:  Curr Opin Pulm Med       Date:  2000-03       Impact factor: 3.155

Review 5.  Molecular mechanisms of endotoxin tolerance.

Authors:  Hongkuan Fan; James A Cook
Journal:  J Endotoxin Res       Date:  2004

6.  Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes.

Authors:  D Ma; P Wu; R W Egan; M M Billah; P Wang
Journal:  Mol Pharmacol       Date:  1999-01       Impact factor: 4.436

7.  Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform.

Authors:  Malcolm Shepherd; Theresa McSorley; Aileen E Olsen; Lee Ann Johnston; Neil C Thomson; George S Baillie; Miles D Houslay; Graeme B Bolger
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

8.  Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum.

Authors:  Daniel Dlaboga; Hassan Hajjhussein; James M O'Donnell
Journal:  Neuropharmacology       Date:  2007-12-23       Impact factor: 5.250

9.  Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons.

Authors:  Carrol D'Sa; Lara M Tolbert; Marco Conti; Ronald S Duman
Journal:  J Neurochem       Date:  2002-05       Impact factor: 5.372

Review 10.  Toll-like receptors. II. Distribution and pathways involved in TLR signalling.

Authors:  F Sandor; M Buc
Journal:  Folia Biol (Praha)       Date:  2005       Impact factor: 0.906

View more
  3 in total

1.  Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.

Authors:  Seiko Susuki-Miyata; Masanori Miyata; Byung-Cheol Lee; Haidong Xu; Hirofumi Kai; Chen Yan; Jian-Dong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 2.  Targeting Phosphodiesterases-Towards a Tailor-Made Approach in Multiple Sclerosis Treatment.

Authors:  Melissa Schepers; Assia Tiane; Dean Paes; Selien Sanchez; Ben Rombaut; Elisabeth Piccart; Bart P F Rutten; Bert Brône; Niels Hellings; Jos Prickaerts; Tim Vanmierlo
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

Review 3.  Phosphodiesterase 4B: Master Regulator of Brain Signaling.

Authors:  Amy J Tibbo; George S Baillie
Journal:  Cells       Date:  2020-05-19       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.